Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment DOI Creative Commons

Suming Wang,

Victor Zota,

Melanie Y. Vincent

и другие.

npj Precision Oncology, Год журнала: 2024, Номер 8(1)

Опубликована: Дек. 3, 2024

Abstract Despite the development of cancer biomarkers and targeted therapies, most patients do not have a specific biomarker directly associated with effective treatment options. We developed VT1021 that induces expression thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to tumor microenvironment (TME). Our studies identified CD36 CD47 as dual can be used patient stratifying tools prognostic for treatment.

Язык: Английский

Peptide‑based therapeutic strategies for glioma: current state and prospects DOI
Yajing Mi,

Pengtao Jiang,

Jing Luan

и другие.

Peptides, Год журнала: 2025, Номер 185, С. 171354 - 171354

Опубликована: Фев. 6, 2025

Язык: Английский

Процитировано

0
Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment DOI Creative Commons

Suming Wang,

Victor Zota,

Melanie Y. Vincent

и другие.

npj Precision Oncology, Год журнала: 2024, Номер 8(1)

Опубликована: Дек. 3, 2024

Abstract Despite the development of cancer biomarkers and targeted therapies, most patients do not have a specific biomarker directly associated with effective treatment options. We developed VT1021 that induces expression thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to tumor microenvironment (TME). Our studies identified CD36 CD47 as dual can be used patient stratifying tools prognostic for treatment.

Язык: Английский

Процитировано

0